Schnellsuche
Allgemeine Suche Allgemeine Suche Klinik Allgemeine Suche Industrie
 

Suchformular

Was suchen Sie

Was suchen Sie ?
  • Unsere Produkte
  • Unsere Lösungen
Was suchen Sie ?
1 Wählen Sie eine
FRANCHISE
2 Wählen Sie eine
APPLICATION
3 Wählen Sie ein
PRODUKT

bioMérieux – First-Half 2017 Results

30 August, 2017

  • Solid sales dynamic, with sales up 11.3% over the first half at constant exchange rates and scope of consolidation:
    • €1,134 million in sales
    • Up 13.3% as reported
  • 30-bp improvement in contributive operating margin before non-recurring items, which came out at 15.2% of sales
  • Sharp 18% increase in net income to €101 million
  • 2017 financial targets revised:
    • Organic growth in sales of between 9% and 10%
    • Contributive operating income before non-recurring items of between €330 million and €345 million

Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux has achieved very satisfactory sales and operating results for the first six months of the year. In light of this dynamic performance, as well as the more-favorable-than-expected currency environment, we are able to revise our full-year financial targets upward while pursuing our innovation and development efforts for the long term."


Marcy l'Etoile, August 30, 2017 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 29 under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for six months ended June 30, 2017. The statements had been reviewed by the Statutory Auditors.

Herunterladen
Pioneering diagnostics